Candel Therapeutics, Inc. CADL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -64.6%+75.0pp | -139.6%-14.1pp | -125.5%-91.9pp | -33.6%— | |
| Liquidity | |||||
| Current ratio | 13.5×+10.7× | 2.8×+0.2× | 2.6×-10.2× | 12.8×-3.0× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×-0.7× | 0.9×+0.8× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $0.98-53.2% | $2.09+375% | $0.44-73.4% | $1.66-51.3% | |
| Valuation | |||||
| Market capitalization | $693.87M+192% | $386.05M+806% | $42.6M-17.6% | $51.73M-76.9% | |
| Price / book | 5×+1.8× | 5.8×+2.5× | 3.3×+2.3× | 1.1×-2.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Candel Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Candel Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
